1. Abrahao AC, Castilho RM, Squarize CH, Molinolo AA, dos Santos-Pinto D, Gutkind JS (2010). A role for COX2-derived PGE2 and PGE2-receptor subtypes in head and neck squamous carcinoma cell proliferation. Oral Oncol 46(12):880-887. PMCID:PMC2991505.
  2. *Abuzeid WM, Davis S, Tang AL, Saunders L, Brenner JC, Lin J, Fuchs JR, Light E, Bradford CR, Prince ME, Carey TE. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog. Arch Otolaryngol Head Neck Surg. 2011 May;137(5):499-507. PMCID:PMC3298372.
  3. Adelstein DJ, Moon J, Hanna E, Giri PG, Mills GM, Wolf GT et al. (2010). Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216). Head Neck 32(2):221-228. PMCID: PMC2967367.
  4. Ahsan A, Hiniker SM, Ramanand SG, Nyati S, Hegde A, Helman A, Menawat R, Bhojani MS, Lawrence TS, Nyati MK. Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res. 2010 Apr 1;70(7):2862-9. Epub 2010 Mar 9. PMCID:PMC2848889.
  5. Ahsan A, Hiniker SM, Davis MA, Lawrence TS, Nyati MK. Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization. Cancer Res. 2009 Jun 15;69(12):5108-14. Epub 2009 Jun 9. PMCID: PMC2697971.
  6. Ahsan A, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A, Pratt WB, Jolly S, Gouveia C, Truong K, Van Waes C, Ray D, Lawrence TS, Nyati MK. Wild-type EGFR Is Stabilized by Direct Interaction with HSP90 in Cancer Cells and Tumors. Neoplasia. 2012 Aug;14(8):670-7PMID:22952420
  7. *Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D'Silva NJ, Kapila YL.Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. 2011 April 15; 117(8): 1670Äì1678. Published online 2010 November 29. doi:?10.1002/cncr.25676 PMCID: PMC3117020.
  8. *Ali S, Varghese L, Pereira L, Tulunay-Ugur OE, Kucuk O, Carey TE, Wolf GT, Sarkar FH. Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents. Cancer Lett. 2009 Jun 18;278(2):201-9. Epub 2009 Feb 23. PMCID: PMC3350786.
  9. *Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, Chen Z, Suksta N, Cooley-Zgela T, Ramanand SG, Ahsan A, Nyati MK, Wright JJ, Van Waes C. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clinical Cancer Res. 2011 Sep 1;17(17):5755-64. PMCID: PMC3368806
  10. Arnold SM, Moon J, Williamson SK, Atkins JN, Ou SH, Leblanc M, Urba SG. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest New Drugs. 2011; 29(2): 352-359. PMCID:PMC2892241.
  11. *Arthur AE, Duffy SA, Sanchez GI, Gruber SB, Terrell JE, Hebert JR, Light E, Bradford CR, D'Silva NJ, Carey TE, Wolf GT, Peterson KE, Rozek LS: "Higher micronutrient intake is associated with human papillomavirus-positive head and neck cancer: a case-only analysis." Nutr Cancer, 63(5):734-42, 2011. PMCID: PMC3391594
  12. Arthur AE, Peterson KE, Rozek LS, Taylor JM, Light E, Chepeha DB, H��bert JR, Terrell JE, Wolf GT, Duffy SA; The UM HeadNeck SPORE Program. Pretreatment dietary patterns, weight status, and head and neck squamous cell carcinoma prognosis. Am J Clin Nutr. 2012 Dec 26. [Epub ahead of print] PubMed PMID: 23269814. PMCID: PMC Journal - In Process.
  13. Ash, L., T. N. Teknos, D. Gandhi, S. Patel and S. K. Mukheri. Head and Neck Squamous Cell Carcinoma: CT Perfusion Can Help Noninvasively Predict Intratumoral Microvessel Density. Radiology. 2009 May:251(2): 422-428. PMID: 19276321.
  14. *Ashimori N, Zeitlin BD, Zhang Z, Warner K, Turkienicz IM, Spalding AC, Teknos TN, Wang S, N?r JE. TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis. Mol Cancer Ther. 2009 Apr;8(4):893-903. PMCID:PMC2709836.
  15. *Attar E, Dey S, Hablas A, Seifeldin IA, Ramadan M, Rozek LS, Soliman AS. Head and neck cancer in a developing country: a population-based perspective across 8 years. Oral Oncol. 2010;46(8):591-6. PMCID:PMC3223856.
  16. Azmi AS, Philip PA, Beck FW, Wang Z, Banerjee S, Wang S, Yang D, Sarkar FH, Mohammad RM. MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011 Jan 6;30(1):117-26. PMID:20818437
  17. Bandhlish A, Leon Barnes E, Rabban JT, McHugh JB (2011). Perivascular epithelioid cell tumors (PEComas) of the head and neck: report of three cases and review of the literature. Head Neck Pathol 5(3):233-240. PMCID: PMC3173543.
  18. *Banerjee R, Mani R, Russo N, Scanlon CS, Tsodikov A, Jing X, Cao Q, Palanisamy N, Metwally T, Inglehart RC, Tomlins S, Bradford C, Carey T, Wolf G, Kalyana-Sundaram S, Chinnaiyan A, Varambally S and D'Silva NJ. The tumor suppressor gene rap1GAP is silenced by mir-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene. 2011 Oct 20;30(42):4339-49. PMCID: PMC3154567.
  19. Banerjee R, Henson BS, Russo N, Tsodikov A, D'Silva NJ. Rap1 mediates galanin receptor 2-induced proliferation and survival in squamous cell carcinoma. Cell Signal. 2011 Jul;23(7):1110-8. Epub 2011 Feb 21. PMCID: PMC3090707
  20. Banerjee R, Russo N, Liu M, Van Tubergen E, D'Silva NJ. Rap1 and its Regulatory Proteins: The tumor suppressor, oncogene, tumor suppressor gene axis in head and neck cancer. Small GTPases. 2012 Jul 1;3(3). [Epub ahead of print] PMID:22684501.
  21. Bao L, Gorin MA, Zhang M, Ventura AC, Pomerantz WC, Merajver SD, Teknos TN, Mapp AK, Pan Q. Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer. Cancer Res. 2009 Jul 15;69(14):5829-34. Epub 2009 Jun 30. PMCID: PMC2757013.
  22. Bauernfeind F, Bartok E, Rieger A, Franchi L, N��?ez G, Hornung V (2011). Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol 187(2):613-617. PMCID: PMC3131480.
  23. *Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ et al. (2012). Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother 2012 Jun; 61(6):771-82. PMC Journal-In-Process. PMID:22057678.
  24. Bhojani MS, Nyati MK, Zhao L, Normolle DP, Ross BD, Lawrence TS, Rehemtulla A. Molecular imaging of akt enables early prediction of response to molecular targeted therapy. Transl Oncol. 2011 Jun;4(3):122-5. Epub 2011 Jun 1. PMCID:PMC3104693.
  25. Bhojani MS, Ranga R, Luker GD, Rehemtulla A, Ross BD, Van Dort ME. Synthesis and investigation of a radioiodinated F3 peptide analog as a SPECT tumor imaging radioligand. PLoS One. 2011;6(7):e22418. Epub 2011 Jul 19. PMCID: PMC3139646.

back to top

Bookmark and Share

Contact Us

Carmelita McKeon
Head and Neck SPORE
U-M Comprehensive Cancer Center NCRC
2800 Plymouth Road
Building 100, Room 110
Ann Arbor, MI 48109-2800
PH: 734-615-6245
FX: 734-615-6246